RSO capsules offer a discreet, full-spectrum way to experience Rick Simpson Oil without syringes or taste. This guide explains what RSO capsules are, how they differ from oils and edibles, how dosing works, and why some people prefer them.
The U.S. decision to reschedule cannabis to Schedule III signals federal recognition of medical value. Industry voices examine 280E tax relief, research access, patient impact, and the unresolved limits of reform.
Governor Hochul has signed Senate Bill 2025-S3294A, delivering the most significant update to New York’s medical cannabis program since 2016. The law expands patient access, adds reciprocity, clarifies rights, and permits home cultivation for certified adults.
Canify AG is redefining Germany’s medical cannabis industry through pharmaceutical precision and plant-based innovation. Led by CEO Sascha Mielcarek, the company blends global sourcing with strict compliance to shape Europe’s next era of medical care.
Four 20 Pharma CEO Torsten Greif is redefining medical cannabis in Germany — from EU-GMP supply chains and certified vapes to a historic soccer sponsorship that put plant medicine on the global stage.
At Expopharm Düsseldorf, Honeysuckle spoke with Remexian Pharma leaders Stefan Adomeit and Francesco Baganz about Germany’s rapidly evolving medical market—where patient demand, shrinking margins, and cross-border consolidation are reshaping the future.
If the U.S. cannabis industry shifts into a pharmaceutical model, what happens to the culture built on community, creativity, and flavor? We explore how pharma could reshape weed—and why preserving the experience matters more than ever.
At Expopharm 2025 in Düsseldorf, Europe’s largest pharma trade fair, cannabis was given a dedicated spotlight. The focus on plant-based therapies signaled their growing role in healthcare — once fringe, now central to Europe’s pharmaceutical conversation.
Leaders including Sasho Stefanoski and Jamie L. Pearson joined the Medical Resource Association, Inc. panel, exploring global cannabis lessons, local opportunities, and the need for patient-centered systems built on trust, sustainability, and innovation.
Science in the City International returns to Bordeaux on Sept 11–12, 2025, with global leaders in cannabis science, medicine, and industry. Featuring voices like PHCANN CEO Sasho Stefanoski, the summit blends education, networking, and French elegance at La Cité du Vin.
Enua CEO Albert Schwarzmeier has scaled the German company from 15 to 55 employees and built strong pharmacy partnerships, making it a top-three medical cannabis distributor. With expansion into the UK and Poland ahead, enua is shaping Europe’s fast-growing €2B cannabis market.
enua CEO Albert Schwarzmeier shares the Greek roots of the company’s name and its mission to go beyond patient care — aiming to change society for the better. Stay tuned for the full interview coming soon to Honeysuckle Media.
A new report from BayMedica shows THCV-infused products yielding 23.7% higher margins, CBC’s untapped potential, and gummies leading rare cannabinoid delivery—signaling major growth opportunities for cannabis brands and formulators.
At New York’s Cannabis Means Business conference, Jill Reddish, co-founder of the Global Cannabis Network Collective (GCNC), talks international markets, supply chain innovation, and why community-first collaboration is shaping the future of the cannabis industry.
Slovenia takes a bold leap in cannabis reform, approving one of the world’s most progressive medical marijuana laws while introducing a new proposal to allow limited home cultivation and possession for adults.
